In the case of NB (and other pediatric tumors), a reduction in chemotherapy doses when combined with a PARP inhibitor might be advantageous in reducing the long term toxicity of these drugs, if efficacy is maintained. The gene discussed is PARP1; the disease is neuroblastoma.